Tiziana Life Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tiziana Life Sciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Tiziana Life Sciences: 6 sponsored US clinical trials, 3 recruiting.
Tiziana Life Sciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Active Secondary Progressive Multiple Sclerosis, with 1 trials.
Upper-quartile sponsor footprint
Tiziana Life Sciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
NCT06868628
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
NCT06890923
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
NCT06292923
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
NCT06879067
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
NCT01301391
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
NCT01011439
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
What is open in the Tiziana Life Sciences pipeline
3 recruiting of 6 indexed (50% open); 1 completed (17%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Non-Active Secondary Progressive Multiple Sclerosis (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tiziana Life Sciences: open-pipeline peers nationwide
Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Tiziana Life Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Tiziana Life Sciences page
6 registered trials is a research-attention snapshot, not an endorsement of Tiziana Life Sciences or any single study.
- 3 of Tiziana Life Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Active Secondary Progressive Multiple Sclerosis is the condition Tiziana Life Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Active Secondary Progressive Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tiziana Life Sciences pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.